Roivant Sciences Ltd. (ROIV) recently received approval for LISRAYA, providing a solid commercial foundation for the company. Additionally, their drug brepocitinib has potential to expand into a broader immunology franchise. ROIV's pulmonary drug candidate mosliciguat shows promise for improving vascular resistance and walking distance, potentially becoming a valuable franchise pending Phase 3 trial results. Overall, ROIV's valuation appears attractive if management meets long-term sales targets.
Quant (QNT) experienced a sharp price decline of 4.21% within one hour, falling from $256 to $245 as of early October 7. Over the past 24 hours, QNT's price decreased by 3.34%, with its market capitalization standing at approximately $3.68 billion, r...
Near Protocol (NEAR) experienced a 3.10% price decline within one hour, falling to $5.04 as of 5:41 a.m. ET on October 7. This drop extended its 24-hour loss to 3.65%, with the price decreasing from $5.20 just an hour earlier. During this period, lon...
Crypto analyst Gert Van Lagen predicts XRP could break out of a symmetrical triangle pattern, potentially reaching $50 and a $3 trillion market cap. This forecast implies a 3,200% gain from its current $1.5 price, suggesting a major rally after a con...
Bitcoin's price fell sharply below $84,000, dropping over $2,000 in minutes and causing significant losses among major altcoins like MNT, DOT, and UNI. The total crypto market capitalization declined by more than $60 billion within 24 hours, reaching...
Dollar Tree received $383 million in tariff refunds after courts ruled tariffs under the IEEPA were unauthorized, benefiting the company’s earnings significantly. However, the higher prices paid by shoppers due to tariffs were not reimbursed directly...
